Recent secondary market transactions have propelled Neuralink’s implied valuation from the $9.7 billion post-money level of its June 2025 Series E round to marks between $42 billion and $59.8 billion as of October 2026, reflecting strong investor demand for Musk-linked assets. Clinical progress, including an October 2026 record of 11.32 bits per second in cursor control achieved via an AI model trained on over 50,000 hours of neural data, has reinforced momentum alongside ongoing FDA trials for paralysis and vision-restoration applications. With total primary capital raised near $1.3 billion and limited participants in human studies, sentiment hinges on further regulatory milestones and any additional funding rounds before year-end resolution. Trader consensus in such markets aggregates capital at risk to gauge the likelihood of crossing specific valuation thresholds amid early-stage execution risks.